Measuring instability is difficult because it requires tracing the evolution of multiple subclones coexisting within a tumor. Hence, monitoring genomic instability by means of traditional tissue-based approaches is, unfortunately, largely unfeasible. Sampling blood can overcome this limit. In fact, compared to healthy people’s blood, cancer patients’ blood typically present higher levels of total circulating cell-free DNA (cfDNA). Discovered for the first time in 1948, cfDNA consists of small DNA fragments circulating in bodily fluids; it also contains circulating-tumor DNA (ctDNA), but in a limited amount (no more than 10% of the total cfDNA).
cfDNA analysis enables detecting early genomic aberrations and cancer cell evolution; however, the low amount of circulating cfDNA and the very low proportion of mutated cfDNA molecules make such an approach challenging. Taking advantage of the enhanced sensitivity of sequencing methods allowed by the introduction of molecular barcodes (unique sequences utilized to identify unique DNA fragments for a correct interpretation of DNA sequencing) and of other technological advances such as enhanced bioinformatics filtering pipelines, researchers managed to identify clinically relevant genetic alterations in early-stage cancer patients, reaching a sensitivity of less than 1 mutant template molecule per milliliter of plasma.
Nevertheless, early detection remains an ambitious clinical application of cfDNA analysis. To establish the sensitivity and specificity required for such an approach, a substantial number of cancer patients and healthy controls is needed; furthermore, sources of false positive results exist. In contrast, monitoring overall genomic instability in healthy individuals, rather than the occurrence of a single driving genomic event, could help identify people that might enter into early access screening prevention programs. In a proof of principle study, researchers at the University Hospital Basel, the University of Trieste, the Memorial Sloan Kettering Cancer Center in New York, Tor Vergata University in Rome, and Bioscience Institute in San Marino demonstrated the technical feasibility of extracting and analyzing healthy individuals’ cfDNA to study genomic alterations.
Opening in the United States
Be first to hear when HELIXAFE opens
Register for the waitlist. About one email a week, only about the science.
Join the US waitlistEducational content. Not a substitute for medical advice. HELIXAFE does not diagnose, treat, predict or prevent disease and does not replace recommended cancer screenings.
Last updated
